Tumors hyperprogression phenomenon against the background of the use of PD1 blocators: myths or reality?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A new class of drugs - PD1 and CTLA4 blockers - is increasingly being used in real clinical practice. Along with this, data on cases of unexpectedly rapid growth of the tumor mass after the start of immunotherapy, which leads to a deterioration of the patient’s general condition, are accumulating. Acceleration of tumor growth by at least two times compared with the previously observed rate is called hyperprogression. Not all experts recognize the presence of this phenomenon; many specialists believe that accelerated tumor growth is a natural course of the tumor process. This article describes two clinical cases that meet the criteria for hyperprogression, and also presents a literature review, including a description of other clinical cases and potential immune and molecular genetic mechanisms that may underlie this phenomenon.

Full Text

Restricted Access

About the authors

I. V Samoylenko

N.N. Blokhin National Medical Research Center of Oncology

Email: i.samoylenko@ronc.ru
Department of Tumor Biotherapy

Ya. I Zhulikov

N.N. Blokhin National Medical Research Center of Oncology

Department of Tumor Biotherapy

L. V Demidov

N.N. Blokhin National Medical Research Center of Oncology

Department of Tumor Biotherapy

References

  1. Brower V. Hyperprogressive disease with anti-PD-1 andanti-PD-LI. Lancet. Oncol2016;17(12):e527.
  2. Champiat S., Dercle L., Ammari S., et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin. Cancer Res. 2017;23(8): 1920-28.
  3. Ferrara R., Mezquita L., Texier M., et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 inhibitors or With Single-Agent Chemotherapy. JAMA. Oncol. 2018.
  4. Ferte C., Fernandez M., Hollebecque A., et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I. clinical trials. Clin. Cancer Res. 2014;20(1):246-52.
  5. Lo Russo G., Moro M., Sommariva M., et al. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin. Cancer Res. 2018.
  6. Kurman J.S., Murgu S.D. Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy. J. Thorac. Dis. 2018;10(2): 1124-28.
  7. Kanazu M., Edahiro R., Krebe H., et al. Hyperprogressive disease in patients with nonsmall cell lung cancer treated with nivolumab: A case series. Thorac. Cancer. 2018.
  8. Saada-Bouzid E., Defaucheux C., Karabajakian A., et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 2017;28(7):1605-11.
  9. Faure M., Rochigneux P., Olive D., et al. Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 inhibitors. Front. immunol. 2018;9:797.
  10. Ogata T., Satake H., Ogata M.,et al. Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report. Case Rep. Oncol. 2018;11(1):143-50.
  11. Soria F., Beleni A.I., D'Andrea D., et al. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J. Urol. 2018.
  12. Kato S., Goodman A., Walavalkar V., et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin. Cancer Res. 2017;23(15):4242-50.
  13. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. In. Immunol. 2007;19(7):813-24.
  14. Herbst R.S., Soria J.C., Kowanetz M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-67.
  15. Boussiotis V.A. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N. Engl. J. Med. 2016;375(18):1767-78.
  16. Жуликов Я.И., Самойленко И.В., Демидов Л.В. Механизмы резистентности метастатической меланомы кожи к анти-PD-1 терапии. Российский биотерапевтический журнал. 2018;17(1):34-46.
  17. Yao H., Wang H., Li C., et al. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy Front. Immunol. 2018; 9:1774.
  18. Kleffel S., Posch C., Barthel S.R., et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 2015;162(6):1242-56.
  19. Li H., Li X., Liu S., et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatol. 2017;66(6):1920-33.
  20. Du S., McCall N., Park K., et al. Blockade of Tumor-Expressed PD-1 promotes lung cancer growth. Oncoimmunol. 2018;7(4):e1408747.
  21. Singavi A.K., Menon S., Kilari D., et al. Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) -analysis of somatic alterations (SAs). Ann. Oncol. 2017;28(Suppl. 5):1140PD.
  22. Zuazo M., Arasanz H., Gato-Cahas M., et al. Pre-treatment CD4 senescent T. cells accurately predicts lack of response to PD-L1/PD-1 immune checkpoint blockade in non-small cell lung cancer and correlates with risk of hyperprogression. An. Oncol. 2018;29(Suppl. 8): viii14-viii57.
  23. Xu W., Larbi A. Markers of T. Cell Senescence in Humans. Int. J. Mol. Sci 2017;18(8).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies